Systemic sclerosis (SSc) is a prototypic idio pathic autoimmune disorder characterized by activation of the immune system, chronic inflammation, and ultimately fibrosis. Specific autoantibodies directed against nuclear mol ecules are associated with the different subtypes of this disease, and (because these associations are normally mutually exclusive) are considered diagnostically useful. However, what actually triggers development of these autoantibod ies, and of the other immune abnormalities in SSc, is far from clear. Some researchers have suggested that an initial trigger is the release of 'danger signals' from necrotic or apoptotic cells, and that the immune system responds to these signals by initiating a cascade of events leading to immune activation and an auto antibody response. New data supporting this contention suggest that serum nucleosomes have an important role in the pathogenesis of SSc, mediated by influencing the activa tion of the adaptive immune system, namely B cells and T cells 1 . This is an important and novel observation linking cellderived DNA, the innate immune system and autoimmunity in SSc, and we feel that this avenue of research could lead to novel treatment strategies.
Histones associate with chromatin to form nucleosomes, which consist of histone proteins with 180-200 bp of DNA wrapped around them. These DNA-histone complexes are measurable in serum, but present only at low levels in health. Indeed, elevated levels found elevated levels of serum nucleosomes, and showed that these nucleosomes increased IgG production and proliferation of mouse B cells. They then demonstrated that these nucleosomemediated effects are attenu ated in CD19deficient mice compared with wildtype mice.
These findings are interesting because autoantibodies directed against common nuclear components are frequently found in patients with SSc 5, 6 . The results suggest that nucleosomes can initiate formation of these antibodies via ligation of TLR9, an endo somal TLR that senses nucleic acids. This study's findings also suggest that CD19 is important in this mechanism, as deletion of CD19 in mice attenuated this effect. CD19 is a cellsurface molecule that forms part of a coreceptor complex that regulates Bcell antigen receptor signalling. All these obser vations suggest a model in which damaged or necrotic (or indeed, pyroptotic) cells release DNA in the form of nucleosomes, which then bind to B cells through a CD19mediated and TLR9mediated pathway that leads to autoantibody production.
However, Yoshizaki et al. 1 did not discover the source of the nucleosomes, which might be of prime importance. The pathogenesis of SLE, for instance, is known to involve both nuclear antibodies and defective apoptosis or reduced clearance of apoptotic cells. Perhaps in SSc a similar abnormality in vascular apoptosis is leading to the increase in serum levels of nucleosomes, which then triggers an innate immune response. Remarkably, in CD19deficient mice, these researchers demonstrated a reduction in skin fibrosis, which was not due to any alteration in TLR9 levels as this parameter was similar across the groups. Indeed, isolated B cells from CD19deficient mice exposed to nucleo somes had massively reduced proliferation and IgG production compared with wildtype, nucleosomeexposed B cells, suggesting that CD19 is critical in mediating fibrosis.
of nucleosomes are present in systemic lupus erythematosus (SLE), another connective tis sue disease 2 . In SLE, cell contents (including nucleosomes) are released into the circulation through necrosis, altered apoptosis or pyrop tosis of various cell types, and are thought to trigger the antiDNA antibody response characteristic of the disease 3 . Yoshizaki et al. 1 found elevated serum levels of nucleosomes in patients with SSc and showed that these levels were highest in patients with pulmo nary fibrosis, a potentially lethal consequence of SSc. These researchers observed a strong correlation between serum nucleosome lev els and total IgG levels 1 . They also showed in vitro that these nucleosomes can stimulate the patternrecognition receptor Tolllike receptor (TLR) 9, thereby increasing Tcell production of IL4 and IL17 and enhancing Bcell production of IgG 1 . TLR9 normally only recognizes unmethylated CpGDNA or bacterial and viral DNA 4 . After activation of this receptor, an intracellular signalling cascade involving MyD88 results in Bcell activation via phosphorylation of nuclear factor κB (NFκB) and increased production of IFNα 4 . Thus, activation of TLR9 on B cells leads to proliferation of B cells and increased IgG production 1 . Yoshizaki et al. 1 also showed that production of IgG antibodies and Bcell proliferation increased as a result of nucleo some stimulation. Moreover, using the mouse model of bleomycininduced SSc, they also
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Systemic sclerosis (SSc) is characterized by an abnormal immune response to innocuous antigens that might lead to autoantibody production. New observations suggest that nucleosomes can mediate both IgG production and B-cell proliferation, via Toll-like receptor signalling, and thereby affect the pathogenesis of SSc. Precisely what mechanism lies behind this CD19mediated effect on fibrosis is currently unclear. Yoshizaki et al. 1 speculate that fibrosis is due to the activation of B cells that then secrete the profibrotic cytokine IL6, as autoantibodies are not directly fibrogenic. However, they did not directly demonstrate any increased IL6 pro duction by activated B cells in this study. Our research group has previously shown that IL6 is profibrotic and that this cytokine does medi ate an increase in matrix molecules 7 . It would be interesting to see whether treatment with the Bcelldepleting antibody rituximab reduces sys temic IL6 levels in SSc, and whether this does indeed reduce skin scores, as some case reports have suggested might be the case 8 . Furthermore, we have also demonstrated that sera from patients with SSc contains RNA that is possibly in association with autoantibodies, and that this RNA binds to macrophages (through Fc recep tors and ultimately TLR8) to trigger a profibrotic response 9 . These findings are analogous to those of the present study in that a serumderived nucleic acid (albeit RNA not DNA) binds to immune cells and drives the endosomal TLR signalling mechanism to produce a profibrotic factor-in our study, TIMP1 (tissue inhibitor of metalloproteinase 1, also known as metallopro teinase inhibitor 1). Clear parallels can be drawn between the two studies. We also speculate that the source of the RNA in our study is damaged vasculature. It is not too much of a stretch to envision that both DNA and RNA could be released from the damaged vasculature and translocate to the circulation, where the immune system recognises these nucleic acids and starts a cascade of events resulting in both autoantibody production and release of profibrotic molecules such as IL6 and TIMP1.
Interestingly, Yoshizaki et al. 1 found no correlation between serum levels of nucleo somes and antinuclear antibodies, as one would expect to see. Perhaps one reason for this lack of correlation is that nucleosomes incite polyclonal Bcell activation rather than a specific monoclonal response. Furthermore, rheumatologists now appreciate that the his tone tail components of nucleosomes can be epigenetically modified by posttranslational modifications such as acetylation and meth ylation. This modification of the histone code, as it is called, is part of the epigenetic machinery that dictates gene expression within cells and these modifications are rapid and reversible. It is conceivable that these epi genetic histone modifications are carried in nucleosomes released into the circulation and, therefore, that they could modulate the result ing immune response (for example, towards production of polyclonal or monoclonal anti bodies). The effect might differ according to the exact histone modifications present, such as methylation, acetylation and sumoylation, among many others.
To sum up, this study 1 demonstrates a clear link between cellular damage, inflammation and fibrosis, and suggests several new areas where drug targeting could take place. Firstly, neutralization of the released nucleosomes, which incite the inflammation. Secondly, and perhaps most interestingly, targeting the specific TLR (TLR9). Yoshizaki and col leagues 1 used the mouse TLR9 antagonist OD2088; however, IMO8400 (an antag onist of human TLR7, TLR8 and TLR9) is being investigated in a phase 2 clinical trial in patients with psoriasis, 10 the results of which are eagerly anticipated.
